Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

Hein J. Boot, Iris Wallenburg, Hester E. de Melker, Marie José M Mangen, Annette A M Gerritsen, Nicoline A. van der Maas, Johannes Berkhof, Chris J L M Meijer, Tjeerd G. Kimman

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Scopus)


A persistent infection with human papillomavirus (HPV) is a prerequisite for the development of cervical cancer. Clinical trials with HPV-vaccines have been very successful in preventing persistent HPV16/18 infections, the two most oncogenic HPV-genotypes. We assessed the introduction of universal HPV-vaccination for preadolescent girls in the Dutch National Immunization Programme. Long-term vaccine efficacy, the need and extent of a catch-up programme for young women, and the impact of vaccination on the cervical cancer screening programme are major unresolved issues. Preliminary conservative estimates (80% vaccine efficacy and no effects on the screening programme, transmission rate, non-cervical cancer incidence, and cross protection) predict an acceptable cost-effectiveness ratio for universal vaccination of preadolescent girls.

Original languageEnglish
Pages (from-to)6245-6256
Number of pages12
Issue number33
Publication statusPublished - 14 Aug 2007


  • Cervical cancer
  • Cost-effectiveness ratio
  • HPV-vaccination
  • National Immunization Program
  • The Netherlands

Cite this